Pegfilgrastim

• Use of pegfilgrastim in severe chronic neutropenia Pending
  2024-519009-36-01 Phase II 1 country IRCCS Istituto Giannina Gaslini
• IZABRIGHT-Lung01: Study of Izalontamab Brengitecan (BMS-986507) versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer after… Pending
  2025-521908-22-00 Phase II/III 10 countries Bristol-Myers Squibb Services Unlimited Company
• CAR-T-cell treatment for untreated high risk MANtle Cell Lymphoma Recruiting
  2022-502405-15-01 Phase II 5 countries Klinikum Der Universitat Munchen AöR
• A trial to learn how safe AZD0486 is and how well it works in older or physically weak adults with large B-cell lymphoma when given after R-… Recruiting
  2025-522029-37-00 Phase III 2 countries AstraZeneca AB
• Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer with Disease Progression on or Af… Recruiting
  2025-522400-24-00 Phase II/III 11 countries Bristol-Myers Squibb Services Unlimited Company
• Study of Izalontamab Brengitecan (BMS-986507) versus Treatment of Physician’s Choice in Patients with Previously Untreated, Locally Advanced… Recruiting
  2024-519871-24-00 Phase II/III 10 countries Bristol-Myers Squibb Services Unlimited Company
• A Study to Compare the Efficacy and Safety of Golcadomide in Combination with Rituximab (Golca + R) vs Investigator’s Choice in Participants… Recruiting
  2024-519152-82-00 Phase III 8 countries Celgene Corp.
• HOVON 170 DLBCL: ANTICIPATE: Prevention of ANThracycline-Induced Cardiac dysfunction by dexrazoxane In PATients with diffusE large B-cell ly… Recruiting
  2023-505377-32-00 Phase III 1 country Stichting Hemato-Oncologie voor Volwassenen Nederland (Hovon)
• A Randomized Trial of Trastuzumab Deruxtecan and Biology-Driven Selection of Neoadjuvant Treatment for HER2-positive Breast Cancer Recruiting
  2022-501504-95-00 Phase II 3 countries Karolinska University Hospital
• A Randomized, Open-label, Phase 3 Study of Acalabrutinib in Combination with Rituximab and Reduced Dose CHOP (R-miniCHOP) in Older Adults wi… Recruiting
  2022-501187-18-00 Phase III 2 countries University Of Saarland
• Immunological variables associated to ICI toxicity in cancer patients Recruiting
  2023-505360-11-00 Phase II 1 country Institut Jules Bordet
• A Study to Assess the Efficacy and Safety of Golcadomide and Rituximab in Participants with Newly Diagnosed Advanced Stage Follicular Lympho… Ended
  2024-511304-16-00 Phase II 5 countries Celgene Corp.
• A Study to Compare the Efficacy and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants with Previously Untreated High-… Ended
  2023-510178-15-00 Phase III 17 countries Celgene Corp.
• HOVON 164 HL: Tislelizumab plus Gemcitabine and Cisplatin for Relapsed or Refractory Hodgkin Lymphoma followed by Tislelizumab Consolidation… Ended
  2022-502225-17-00 Phase II 3 countries Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting
• A study to investigate the efficacy and safety of luveltamab tazevibulin versus IC chemotherapy in women with ovarian cancer (including fall… Ended
  2024-512477-27-00 Phase II 9 countries Sutro Biopharma Inc.

Showing 1–15 of 15 trials